SB-258719

SB-258719 is a drug developed by GlaxoSmithKline which acts as a selective 5-HT₇ receptor partial inverse agonist,^[1] and was the first such ligand identified for 5-HT₇.^[2] Its use in research has mainly been in demonstrating the potential use for 5-HT₇ agonists as potential novel analgesics, due to the ability of SB-258719 to block the analgesic effects of a variety of 5-HT₇ agonists across several different testing models.^[3][4][5][6]

SB-258719

Identifiers
IUPAC name (1R)-3,N-dimethyl-N-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzenesulfonamide
CAS Number	195199-95-2 N
PubChem CID	5312148
IUPHAR/BPS	281
ChemSpider	4471578 Y
UNII	GF43CP5LXQ
ChEMBL	ChEMBL12264 Y
CompTox Dashboard (EPA)	DTXSID201029788
Chemical and physical data
Formula	C18H30N2O2S
Molar mass	338.51 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1ccc(C)cc1S(=O)(=O)N(C)C(C)CCN(CC2)CCC2C
InChI InChI=1S/C18H30N2O2S/c1-15-8-11-20(12-9-15)13-10-17(3)19(4)23(21,22)18-7-5-6-16(2)14-18/h5-7,14-15,17H,8-13H2,1-4H3/t17-/m1/s1 Y Key:AGVNHDNTFYHZNL-QGZVFWFLSA-N Y
NY (what is this?)  (verify)